iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details)

Segment Reporting (Details) (USD $)	3 Months Ended		9 Months Ended
Segment Reporting (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Segment Reporting Information [Line Items]
Net revenues	$ 349,000us-gaap_SalesRevenueNet	$ 0us-gaap_SalesRevenueNet	$ 1,535,000us-gaap_SalesRevenueNet	$ 0us-gaap_SalesRevenueNet
Research and development expenses	815,000us-gaap_ResearchAndDevelopmentExpense	343,000us-gaap_ResearchAndDevelopmentExpense	2,731,000us-gaap_ResearchAndDevelopmentExpense	1,480,000us-gaap_ResearchAndDevelopmentExpense
General and administrative expenses	1,222,000us-gaap_GeneralAndAdministrativeExpense	951,000us-gaap_GeneralAndAdministrativeExpense	3,574,000us-gaap_GeneralAndAdministrativeExpense	2,950,000us-gaap_GeneralAndAdministrativeExpense
Operating loss	(1,688,000)us-gaap_OperatingIncomeLoss	(1,294,000)us-gaap_OperatingIncomeLoss	(4,770,000)us-gaap_OperatingIncomeLoss	(2,689,000)us-gaap_OperatingIncomeLoss
Total assets	11,446,000us-gaap_Assets		11,446,000us-gaap_Assets		6,494,000us-gaap_Assets
iBio Brazil [Member]
Segment Reporting Information [Line Items]
Net revenues	0		0
Research and development expenses	0		0
General and administrative expenses	35,000		86,000
Operating loss	(35,000)		(86,000)
Total assets	63,000		63,000
iBio [Member]
Segment Reporting Information [Line Items]
Net revenues	349,000		1,535,000
Research and development expenses	815,000		2,731,000
General and administrative expenses	1,187,000		3,488,000
Operating loss	(1,653,000)		(4,684,000)
Total assets	$ 11,383,000		$ 11,383,000

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References + Details